ERCC1 and personalized medicine in lung cancer.

Ryu, Jeong Seon; Memon, Azra; Lee, Seul-Ki

Ryu, Jeong Seon; Memon, Azra; Lee, Seul-Ki.

Afiliação

Ryu JS; Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.
Memon A; Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.
Lee SK; Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.

Ann Transl Med ; 2(4): 32, 2014 Apr.

Article em En | MEDLINE | ID: mdl-25333008

ABSTRACT

ABSTRACT

Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.

Palavras-chave

Biomarker; excision repair cross-complementing group 1 (ERCC1); non-small-cell lung cancer; personalized medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Transl Med Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google